An Experimental Treatment Failed in Mice, and Researchers Did the Right Thing: They Published About It

The knowledge could help steer scientists toward more promising approaches.

UConn Professor of Molecular and Cell Biology David Goldhamer, Alexion Pharmaceuticals researcher Jeffrey Hunter, and colleagues worked for years to discover a potential antibody therapy for FOP using accurate genetic mouse models of the disease developed by the two groups. The idea was that the antibody would block the mutant receptor and prevent the responsible stem cells from making new bone. But the results were exactly the opposite.

See story in UConn Today